Lonardo Amedeo, Weiskirchen Ralf
Department of Internal Medicine, Azienda Ospedaliero-Universitaria of Modena (-2023), 41126 Modena, Italy.
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Rheinisch-Westfälische Technische Hochschule (RWTH), University Hospital Aachen, D-52074 Aachen, Germany.
Metabolites. 2024 Jul 26;14(8):408. doi: 10.3390/metabo14080408.
Metabolic health is tightly regulated by neuro-hormonal control, and systemic metabolic dysfunction may arise from altered function of the hypothalamic-anterior pituitary axis (HAPA). Ancient experimental observations of hypothalamic obesity (HO) and liver cirrhosis occurring among animals subjected to hypothalamic injury can now be explained using the more recent concepts of lipotoxicity and metabolic dysfunction-associated steatotic liver disease (MASLD). Lipotoxicity, the range of abnormalities resulting from the harmful effects of fatty acids accumulated in organs outside of adipose tissue, is the common pathogenic factor underlying closely related conditions like hypothalamic syndrome, HO, and MASLD. The hormonal deficits and the array of metabolic and metabolomic disturbances that occur in cases of HO are discussed, along with the cellular and molecular mechanisms that lead, within the MASLD spectrum, from uncomplicated steatotic liver disease to steatohepatitis and cirrhosis. Emphasis is placed on knowledge gaps and how they can be addressed through novel studies. Future investigations should adopt precision medicine approaches by precisely defining the hormonal imbalances and metabolic dysfunctions involved in each individual patient with HO, thus paving the way for tailored management of MASLD that develops in the context of altered HAPA.
代谢健康受到神经激素控制的严格调节,下丘脑-垂体前叶轴(HAPA)功能改变可能导致全身代谢功能障碍。现在可以用脂毒性和代谢功能障碍相关脂肪性肝病(MASLD)的最新概念来解释古代对下丘脑损伤动物中出现的下丘脑性肥胖(HO)和肝硬化的实验观察结果。脂毒性是指脂肪组织外器官中积累的脂肪酸产生有害影响所导致的一系列异常,是下丘脑综合征、HO和MASLD等密切相关疾病的共同致病因素。本文讨论了HO病例中出现的激素缺乏以及一系列代谢和代谢组学紊乱,以及在MASLD范围内,从单纯性脂肪性肝病发展到脂肪性肝炎和肝硬化的细胞和分子机制。重点关注知识空白以及如何通过新的研究来解决这些问题。未来的研究应采用精准医学方法,精确界定每例HO患者所涉及的激素失衡和代谢功能障碍,从而为在HAPA改变的背景下发展而来的MASLD的个性化管理铺平道路。